CTLA4 and gastric cancer: Imbalance between the gastric microbiome and host promotes the development of GC.11 A recent study showed that the microbiome of GC patients affects the treatment response to immune checkpoint blockade drugs, such as anti-PD-1 and anti-CTLA-4.